Association between race, depression, and antiretroviral therapy adherence in a low-income population with HIV infection

Journal of General Internal Medicine

Volumn 27, Issue 9, 2012, Pages 1159-1164

  Kong, Meg C ^a   Nahata, Milap C ^a   Lacombe, Veronique A ^a   Seiber, Eric E ^a   Balkrishnan, Rajesh ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adherence; Depression; HIV; Medicaid; Race

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MEDICAID; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RACE DIFFERENCE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIDEPRESSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DEPRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POVERTY; RETROSPECTIVE STUDIES;

EID: 84866950955     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-012-2043-3     Document Type: Article

References (48)

1. Kraut-Becher J, Eisenberg M, Voytek C, Brown T, Metzger DS, Aral S. Examining racial disparities in HIV. J Acquir Immune Defic Syndr. 2008;47(Suppl 1):S20-S27.
2. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520-529.
3. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States. JAMA. 1999;281:2305-2315.
4. Cunningham WE, Anderson RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37:1270-1281.
5. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96.
6. Palacio H, Kahn JG, Richards TA, et al. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Reports (Washington, DC: 1974), June 2002. 117(3):233-251; discussion 231-232.
7. CDC. HIV/AIDS Surveillance Report, 2007. Vol. 19. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at http://www.cdc.gov/hiv/surveillance/resources/reports/2007report/index.htm. Accessed February 20, 2012.
8. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2009. National Vital Statistics Report, vol. 57, no. 14. Available at http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57-14.pdf. Accessed February 20, 2012.
9. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2001;26:82-92.
10. Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the multicenter AIDS cohort study. AIDS. 2004;18:683-688.
11. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. JIDS. 2005;38:320-328.
12. Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among white, Hispanic, and black men in the MACS cohort. J Acquir Immune Defic Syndr. 2009;52:290-293.
13. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386- 395.
14. Golin C, Liu H, Hays R, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765.
15. Thrasher AD, Earp JAL, Golin CE, et al. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:84-93.
16. Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on Efavirenz-Containing regimens for initial HIV therapy. J Acquir Immune Defic Syndr. 2007;46:547-554.
17. Weiser SD, Riley ED, Ragland K, Hammer G, Clark R, Bangsberg DR. Brief report: factors associated with depression among homeless and marginally housed HIV Infected men in San Francisco. J Gen Intern Med. 2006;21:61-64.
18. Asch S, Kilbourne A, Gifford A, et al. Underdiagnosis of depression in HIV. J Gen Intern Med. 2003;18:450-460.
19. Yun LW, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIVinfected patients. J Acquir Immune Defic Syndr. 2005;38:432-438.
20. Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a Meta-analysis. J Gen Intern Med. 2011;26:1175-1182.
21. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
22. Shacham E, Nurutdinova D, Satyanarayana V, et al. Routine screening for depression: identifying a challenge for successful HIV care. AIDS Patient Care STDS. 2009;23:949-955.
23. Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002;30:401-409.
24. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285:1466-1474.
25. Burack JH, Barrett DC, Stall RD, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568- 2573.
26. Leserman J, Petitto JM, Perkins DO, et al. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. a 2-year follow-up study. Arch Gen Psychiatry. 1997;54:279-285.
27. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:384-90.
28. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394- 402.
29. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-1769.
30. Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418-428.
31. Robinson MJ, Qaqish RB. Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatr Clin North Am. 2002;25:149-175.
32. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156:101-107.
33. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIVinfected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Jul 8, 2008. pp. 1- 98. Available at http://aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf. Accessed February 20, 2012.
34. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed February 20, 2012.
35. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
36. Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911-925.
37. Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167-73.
38. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
39. Martin M, Del CE, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263-1268.
40. Kyser M, Buchacz K, Bush TJ, et al. Factors associated with nonadherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23(5):601-611.
41. Lima VD, Harrigan R, Murry M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371-2380.
42. Boulware LE, Cooper LA, Ratner LE, et al. Race and trust in the health care system. Public Health Rep. 2003;118:358-65.
43. Das AK, Olfson M, McCurtis HL, et al. Depression in African Americans: breaking barriers to detection and treatment. J Fam Pract. 2006;55:30-39.
44. Melfi CA, Croghan TW, Hanna MP, et al. Racial variation in antidepressant treatment in a Medicaid population. J Clin Psychiatry. 2000;16:16-21.
45. Dunlop DD, Song J, Lyons JS, Mannheim LM, Chang RW. Racial/ethnic differences in rates of depression among pre-retirement adults. Am J Public Health. 2003;93:1945-1952.
46. Kessler RC, Berglund P, Demler O, et al. National comorbidity survey replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
47. Walkup JT, Boyer CA, Kellermann SL. Reliability of Medicaid claims files for use in psychiatric diagnoses and service delivery. Adm Policy Ment Health. 2000;27:129-139.
48. Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care. 2001;39:1188-1202.